Quanterix Digital Immunoassay for Prostate Specific Antigen Improves Analytical Performance

CAMBRIDGE, Mass., July 21, 2011 /PRNewswire/ -- Quanterix Corporation, an in-vitro diagnostics (IVD) company providing life science researchers and IVD labs single molecule technology with unprecedented sensitivity and precision, announced that the analytical performance of AccuPSA™, a fifth-generation digital immunoassay for Prostate Specific Antigen (PSA), demonstrated a robust 2-log improvement in sensitivity over today's ultrasensitive third-generation assays for measuring PSA in patients following radical prostatectomy.  The company's proprietary Single Molecule Array (SiMoA™) technology platform combines both digital and analog detection in one straightforward measurement, thereby broadening the range of protein detection that can be acquired from a small sample size.   Data will be presented at the American Association for Clinical Chemistry (AACC) 2011 Annual Meeting held July 24-28 in Atlanta, GA.  

"Because a radical prostatectomy removes the tissue responsible for producing PSA, measuring this protein in patients following surgery is very difficult with the assays available today," explains David Wilson Ph.D., Senior Director, Product Development at Quanterix and lead author of the study.  "The 1000-fold improvement in sensitivity from SiMoA enables us to accurately measure PSA levels in all post radical prostatectomy patients tested.   AccuPSA has the potential to provide precise and reliable measurements of a patients' PSA levels post surgery, which could enable risk stratification for cancer recurrence based on a single blood test.  This test could be a significant advance for physicians to determine the right treatment and monitoring plan going forward."

These data are part of a follow-up retrospective pilot study conducted by Quanterix that was designed to determine the ability of the test to predict 5-year biochemical recurrence-free survival following radical prostatectomy.  Data presented at the AACC will focus on the analytical performance of the AccuPSA test.  Clinical utility was also demonstrated and these results will be published later this year in a prominent peer-reviewed journal.

Poster Presentation Information:
Abstract # A-47
Analytical Performance of AccuPSA™, a Fifth-generation Digital Immunoassay for Prostate Specific Antigen
Session: 02/Cancer/Tumor Markers
Date/Time: 7/26/2011 10:00:00 AM

About Quanterix

Quanterix Corporation is developing its proprietary Single Molecule Array (SiMoA™) technology for the in vitro diagnostics and life science research markets. The digital nature of SiMoA yields unprecedented assay performance, stemming from a 1,000-fold improvement in sensitivity compared with today's analog only technology. SiMoA will enable researchers in life science to validate novel, low abundance biomolecules from a single droplet of blood, leading to greater insight into disease detection, diagnosis, therapy selection and disease monitoring. Automated systems based on SiMoA will provide diagnostic test information to healthcare practitioners faster, with greater reliability, unprecedented range and increased cost effectiveness.  Founded in 2007, the privately held Cambridge, Massachusetts-based company is backed by leading life science investors including ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures. For additional information, please visit www.quanterix.com.

SOURCE Quanterix Corporation